Evotec OAI undergoes successful FDA inspection

Published: 21-Jun-2004

Evotec OAI, a partner for integrated, high-value-added drug discovery and development solutions, has undergone a successful combined general GMP audit and FDA pre-approval inspection of its cGMP manufacturing facilities to manufacture a sophisticated active pharmaceutical ingredient (API).


Evotec OAI, a partner for integrated, high-value-added drug discovery and development solutions, has undergone a successful combined general GMP audit and FDA pre-approval inspection of its cGMP manufacturing facilities to manufacture a sophisticated active pharmaceutical ingredient (API).

Dr Mario Polywka, president chemical and pharmaceutical development division at Evotec OAI, said: 'Following our successful inspection for the manufacture of an approved API in 1999, it is again gratifying to receive validation of our high quality process development, manufacturing, analytical and quality assurance capabilities through this audit. This confirms the position of Evotec OAI's CPD division as a world leader in the supply of customer's development needs through its EVOdevelop platform.'

You may also like